Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 47,000 shares of common stock.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Pasadena. CA | Posted on December 18th, 2018

The strike price of options is set at an exercise price per share of $13.66, the last reported closing price of the Company's common stock on December 10, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of one new employee, anticipated to be within 60 days of the date of the approval. The grants are outside of the Company's stockholder-approved equity incentive plans. The options vest and become exercisable over a period of four years.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Gold nanoparticles to facilitate in-situ detection of amplified DNA at room temperature March 21st, 2019

CEA-Leti Announces Prototype of Next-generation Photo-Acoustic Sensors for Gas Detection: REDFINCH Team Achieves These Capabilities in Mid-infrared Region, Where Many Important Chemical and Biological Species Have Strong Absorption Fingerprints March 21st, 2019

Fish-Inspired Material Changes Color Using Nanocolumns March 18th, 2019

New method to reduce uranium concentration in contaminated water March 18th, 2019

Jobs

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Participate in the development of Malaysia’s National Graphene Action Plan 2020 October 10th, 2016

Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016

Investments/IPO's/Splits

Nanometrics Announces $80 Million Share Repurchase Program March 14th, 2019

A Nanobiotechnology Startup from a small town in India attracts the Global Investors January 27th, 2019

Nanobiotix Plans to Conduct Registered Public Offering in the United States January 17th, 2019

Nanometrics to Participate in the 21st Annual Needham Growth Conference January 7th, 2019

Nanomedicine

Gold nanoparticles to facilitate in-situ detection of amplified DNA at room temperature March 21st, 2019

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia March 11th, 2019

New optical imaging system could be deployed to find tiny tumors: Near-infrared technology pinpoints fluorescent probes deep within living tissue; may be used to detect cancer earlier March 8th, 2019

Computer-designed vaccine elicits potent antibodies against RSV: The nanoparticle platform for this respiratory syncytial virus study will be applied to vaccine research on flu, HIV, and more; Seattle startup Icosavax will advance related clinical trials March 8th, 2019

Announcements

Gold nanoparticles to facilitate in-situ detection of amplified DNA at room temperature March 21st, 2019

CEA-Leti Announces Prototype of Next-generation Photo-Acoustic Sensors for Gas Detection: REDFINCH Team Achieves These Capabilities in Mid-infrared Region, Where Many Important Chemical and Biological Species Have Strong Absorption Fingerprints March 21st, 2019

Fish-Inspired Material Changes Color Using Nanocolumns March 18th, 2019

New method to reduce uranium concentration in contaminated water March 18th, 2019

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Fish-Inspired Material Changes Color Using Nanocolumns March 18th, 2019

Quantum sensing method measures minuscule magnetic fields: MIT researchers find a new way to make nanoscale measurements of fields in more than one dimension March 15th, 2019

Researchers reverse the flow of time on IBM's quantum computer March 14th, 2019

Pushing Past Limits: Junkai Jiang receives prestigious Ph.D. Student Fellowship from IEEE Electron Devices Society March 14th, 2019

Nanobiotechnology

Gold nanoparticles to facilitate in-situ detection of amplified DNA at room temperature March 21st, 2019

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia March 11th, 2019

Computer-designed vaccine elicits potent antibodies against RSV: The nanoparticle platform for this respiratory syncytial virus study will be applied to vaccine research on flu, HIV, and more; Seattle startup Icosavax will advance related clinical trials March 8th, 2019

Nanotechnology Gives Mice Night Vision—Are Humans Next? March 2nd, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project